NASDAQ:SLDB - Solid Biosciences Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$23.39 -0.19 (-0.81 %)
(As of 12/14/2018 02:37 PM ET)
Previous Close$23.58
Today's Range$22.86 - $24.10
52-Week Range$6.83 - $54.84
Volume160,746 shs
Average Volume213,656 shs
Market Capitalization$827.70 million
P/E Ratio-8.12
Dividend YieldN/A
BetaN/A
Solid Biosciences Inc. engages in identifying and developing therapies for duchenne muscular dystrophy in the United States. Its lead product candidate includes SGT-001, a gene therapy that is in Phase I/II clinical trials to restore functional dystrophin protein expression in patients' muscles. The company's product candidates also comprise SB-001, a monoclonal antibody to reduce fibrosis and inflammation. In addition, it is developing soft wearable assistive devices that have functional and therapeutic benefits to DMD patients. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Receive SLDB News and Ratings via Email

Sign-up to receive the latest news and ratings for SLDB and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SLDB
Previous Symbol
CUSIPN/A
Phone617-337-4680

Debt

Debt-to-Equity RatioN/A
Current Ratio13.96
Quick Ratio13.96

Price-To-Earnings

Trailing P/E Ratio-8.12
Forward P/E Ratio-10.68
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book Value($1.73) per share
Price / Book-13.52

Profitability

EPS (Most Recent Fiscal Year)($2.88)
Net Income$-52,110,000.00
Net MarginsN/A
Return on Equity-63.10%
Return on Assets-45.38%

Miscellaneous

Employees60
Outstanding Shares35,430,000
Market Cap$827.70 million
OptionableOptionable

Solid Biosciences (NASDAQ:SLDB) Frequently Asked Questions

What is Solid Biosciences' stock symbol?

Solid Biosciences trades on the NASDAQ under the ticker symbol "SLDB."

How were Solid Biosciences' earnings last quarter?

Solid Biosciences Inc (NASDAQ:SLDB) released its earnings results on Tuesday, November, 13th. The company reported ($0.55) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.56) by $0.01. View Solid Biosciences' Earnings History.

When is Solid Biosciences' next earnings date?

Solid Biosciences is scheduled to release their next quarterly earnings announcement on Thursday, April 4th 2019. View Earnings Estimates for Solid Biosciences.

What price target have analysts set for SLDB?

9 brokerages have issued 1-year price targets for Solid Biosciences' stock. Their forecasts range from $28.00 to $60.00. On average, they expect Solid Biosciences' share price to reach $43.3750 in the next twelve months. This suggests a possible upside of 85.2% from the stock's current price. View Analyst Price Targets for Solid Biosciences.

What is the consensus analysts' recommendation for Solid Biosciences?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Solid Biosciences in the last year. There are currently 2 sell ratings, 3 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Solid Biosciences.

What are Wall Street analysts saying about Solid Biosciences stock?

Here are some recent quotes from research analysts about Solid Biosciences stock:
  • 1. According to Zacks Investment Research, "Solid Biosciences LLC is a life science company. It focuses on developing therapies for Duchenne muscular dystrophy. The company is engaged in developing gene therapies, disease modifying therapies and assistive devices, all targeting the various facets of the DMD. Its product candidate includes SGT-001, a gene transfer candidate which is in Phase I/II clinical trial to restore functional dystrophin protein expression in patients' muscles. Solid Biosciences LLC is headquartered in Cambridge, Massachusetts. " (10/24/2018)
  • 2. Chardan Capital analysts commented, "We increase our SLDB PT to $60 (from $37.50) on recent reports of efficacy shown for AAV-based gene therapies (GTs) in Duchenne muscular dystrophy (DMD) across several ongoing trials, including Solid’s trial. Our PT increase is also driven by the 18 June announced resolution of the clinical hold on SGT-001. We believe early patient reports (see bullets below) suggest breakthroughs could be in progress for AAV- based gene therapies for DMD being developed by Therapeutics (unrated), and Pfizer (unrated). Positive early data from clinical trials from 3 different companies, to us, supports the utility of microdystrophin GT in a devastating disease with no effective approved therapies. therefore update our Chardan DMD Model (discussed below; see Figure 1), which drives our SLDB PT increase to $60." (6/24/2018)

Has Solid Biosciences been receiving favorable news coverage?

Media stories about SLDB stock have trended somewhat positive on Friday, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Solid Biosciences earned a media sentiment score of 1.8 on InfoTrie's scale. They also gave news articles about the company a news buzz of 3.0 out of 10, indicating that recent media coverage is unlikely to have an impact on the stock's share price in the next few days.

Are investors shorting Solid Biosciences?

Solid Biosciences saw a increase in short interest in November. As of November 15th, there was short interest totalling 1,912,850 shares, an increase of 33.5% from the October 31st total of 1,432,682 shares. Based on an average daily trading volume, of 328,923 shares, the days-to-cover ratio is currently 5.8 days. Approximately 8.9% of the company's stock are short sold. View Solid Biosciences' Current Options Chain.

Who are some of Solid Biosciences' key competitors?

Who are Solid Biosciences' key executives?

Solid Biosciences' management team includes the folowing people:
  • Mr. Ilan Ganot, Co-Founder, CEO, Pres & Director (Age 44)
  • Ms. Jennifer Ziolkowski CPA, CFO, Treasurer & Assistant Sec. (Age 44)
  • Dr. Jorge A. Quiroz M.D., Chief Medical Officer (Age 48)
  • Dr. Andrey Zarur Ph.D., Co-Founder & Chairman of Directors (Age 47)
  • Ms. Annie Ganot, Co-Founder & Patient Advocacy

When did Solid Biosciences IPO?

(SLDB) raised $130 million in an initial public offering (IPO) on Friday, January 26th 2018. The company issued 7,000,000 shares at $18.00-$19.00 per share. J.P. Morgan, Goldman Sachs and Leerink Partners served as the underwriters for the IPO and Nomura and Chardan were co-managers.

Who are Solid Biosciences' major shareholders?

Solid Biosciences' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include JPMorgan Chase & Co. (8.63%), Partner Fund Management L.P. (2.26%), BlackRock Inc. (2.20%), Vanguard Group Inc. (1.91%), Vanguard Group Inc (1.91%) and Janus Henderson Group PLC (1.45%). Company insiders that own Solid Biosciences stock include Ilan Ganot, Joel Solomon Zev Schneider, Jorge Armando Quiroz, Juan Andrey Zarur, Life Sciences Maste Perceptive and Pedro Alvaro Amorrortu. View Institutional Ownership Trends for Solid Biosciences.

Which institutional investors are selling Solid Biosciences stock?

SLDB stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Foresite Capital Management III LLC and Artal Group S.A.. Company insiders that have sold Solid Biosciences company stock in the last year include Ilan Ganot, Joel Solomon Zev Schneider, Jorge Armando Quiroz, Juan Andrey Zarur and Pedro Alvaro Amorrortu. View Insider Buying and Selling for Solid Biosciences.

Which institutional investors are buying Solid Biosciences stock?

SLDB stock was acquired by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Partner Fund Management L.P., Vanguard Group Inc, Vanguard Group Inc., FMR LLC, BlackRock Inc., Morgan Stanley and Bank of New York Mellon Corp. View Insider Buying and Selling for Solid Biosciences.

How do I buy shares of Solid Biosciences?

Shares of SLDB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Solid Biosciences' stock price today?

One share of SLDB stock can currently be purchased for approximately $23.42.

How big of a company is Solid Biosciences?

Solid Biosciences has a market capitalization of $827.70 million. The company earns $-52,110,000.00 in net income (profit) each year or ($2.88) on an earnings per share basis. Solid Biosciences employs 60 workers across the globe.

What is Solid Biosciences' official website?

The official website for Solid Biosciences is http://www.solidbio.com.

How can I contact Solid Biosciences?

Solid Biosciences' mailing address is 141 PORTLAND STREET FIFTH FLOOR, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-337-4680.


MarketBeat Community Rating for Solid Biosciences (NASDAQ SLDB)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  120 (Vote Outperform)
Underperform Votes:  93 (Vote Underperform)
Total Votes:  213
MarketBeat's community ratings are surveys of what our community members think about Solid Biosciences and other stocks. Vote "Outperform" if you believe SLDB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SLDB will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/14/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel